ENTITY

Immix Biopharma Inc (IMMX US)

24
Analysis
Health CareUnited States
Immix Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing a novel class of tissue-specific therapeutics in oncology and inflammation to treat inflammatory bowel disease, including ulcerative colitis and crohn's diseases. Immix Biopharma serves customers in the United States.
more
Refresh
03 Apr 2024 19:10Issuer-paid

Immix Biopharma - Reaffirmed long-term focus on outpatient CAR-T

Immix Biopharma is continuing its strategic pivot towards exploring non-traditional indications for its CAR-T asset, NXC-201, leading with...

Share
26 Mar 2024 19:10Issuer-paid

Immix Biopharma - Marching towards US clinical trials for NXC-201

Immix Biopharma is closer to dosing its first US patient for lead CAR-T asset NXC-201, with the appointment of the Memorial Sloan Kettering Cancer...

Share
27 Feb 2024 19:10Issuer-paid

Immix Biopharma - 2023 recap with a preview of active year ahead

IMMX has shared a 12-month recap, capturing key clinical and regulatory events from 2023, setting the stage for an active 2024. Its lead CAR-T...

Share
13 Feb 2024 01:10Issuer-paid

Immix Biopharma - Updates galore: NXC-201 ODD (EU) and raise

Immix Biopharma has released back-to-back updates, including EU orphan drug designation (ODD) for its lead CAR-T asset NXC-201, addressing amyloid...

Share
07 Feb 2024 19:10Issuer-paid

Immix Biopharma - Increased legroom following common-only raise

Immix Biopharma has announced a $15m (gross), fully underwritten equity issue. The company will use the proceeds to fund clinical trials for lead...

Share
x